Who is sponsoring NCT05097768?

NCT05097768 is sponsored by Alfarabi Colleges.

What drugs are being tested in NCT05097768?

Interventions in NCT05097768: Dexamethasone 0.5mg, Ketorolac 10 Mg Oral Tablet, Meloxicam 7.5 mg, Ibuprofen 600 mg, Placebo.

What condition does NCT05097768 study?

NCT05097768 studies Symptomatic Irreversible Pulpitis.

Is NCT05097768 still recruiting?

NCT05097768 is currently completed. Last updated 14 February 2022.

Last reviewed 2022-02-14 · How we verify

NCT05097768

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of Premedication on the Success Rate of Inferior Alveolar Nerve Block

Completed NA Last updated 14 February 2022

What this trial tests

NA trial testing Dexamethasone 0.5mg in Symptomatic Irreversible Pulpitis in 250 participants. Completed in 27 January 2022.

Timeline

15 August 2021

Primary endpoint
15 January 2022

27 January 2022

Quick facts

Lead sponsor	Alfarabi Colleges
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	250
Start date	15 August 2021
Primary completion	15 January 2022
Estimated completion	27 January 2022
Sites	1 location across Saudi Arabia

Drugs / interventions tested

Dexamethasone 0.5mg — full drug profile →
Ketorolac 10 Mg Oral Tablet — full drug profile →
Meloxicam 7.5 mg — full drug profile →
Ibuprofen 600 mg — full drug profile →
Placebo

Conditions studied

Symptomatic Irreversible Pulpitis — all drugs for Symptomatic Irreversible Pulpitis →

Sponsor

Alfarabi Colleges

Who can join

18 and older, any sex, with Symptomatic Irreversible Pulpitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose: The aim of this prospective, double-blind, randomized controlled trial is to compare the effect of oral premedication of dexamethasone, ketorolac, meloxicam, ibuprofen or placebo on the success of inferior alveolar nerve blocks (IANB) of mandibular posterior teeth in patients experiencing symptomatic irreversible pulpitis. Methods: The trial will include five study groups, each consists of 50 patients who exhibits symptomatic irreversible pulpitis of a mandibular first or second molar. The patients will receive identically appearing capsules containing either dexamethasone 0.5 mg, ketorolac 10 mg, meloxicam 7.5 mg, ibuprofen 600 mg, or placebo by mouth 60 minutes before the administration of an IANB. Endodontic access will begin 15 minutes after completion of the IANB. The IANB success is defined as no or mild pain (Heft Parker visual analog scale recordings) on pulpal access or instrumentation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexamethasone 0.5mg

Trials testing the same drug.

NCT05070468 — Effect of Dexamethasone on Labor Induction · Phase 3 · completed

Other recruiting trials for Symptomatic Irreversible Pulpitis

Currently open trials in the same condition.

NCT07410780 — Postoperative Pain After Root Canal Obturation Using Bioceramic and Calcium Hydroxide Sealers · NA · recruiting
NCT07290049 — Postoperative Pain After Pulpotomy in Children Using Calcium Silicate Cements With and Without Laser Therapy · NA · recruiting
NCT06640231 — The Effect of XP-Endo Finisher Activation of Bioceramic Sealer on Postoperative Pain in Mandibular First Molar With Symp · NA · recruiting
NCT06525844 — Regenerative Endodontic Therapy in Cases of Irreversible Pulpitis · NA · recruiting

Other Alfarabi Colleges trials

Trials by the same sponsor.

NCT04961268 — Effect of Preoperative Oral Tramadol on Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05097768 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alfarabi Colleges
Last refreshed: 14 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05097768.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing